Zepp Health Signs Three-Year Global Partnership with HYROX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Should l Buy ZEPP?
Amazfit, a smart wearable brand owned by Zepp Health, announced a new three-year global partnership with HYROX, expanding the existing regional collaboration into a worldwide agreement. "We're excited to take this partnership with HYROX to the next level," said Wayne Huang, CEO of Zepp Health. "HYROX has built strong momentum and is rapidly expanding as a global fitness community. This expanded partnership reflects a shared commitment to enhancing the experience of HYROX athletes and participants through Amazfit's smart wearables and connected training technologies."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZEPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZEPP
Wall Street analysts forecast ZEPP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.010
Low
64.37
Averages
64.37
High
64.37
Current: 18.010
Low
64.37
Averages
64.37
High
64.37
No data
About ZEPP
Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has two reportable segments the Xiaomi wearable products segment and Self-branded products and others segment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zepp Health Files 2025 Annual Report with SEC
- Annual Report Submission: On April 24, 2026, Zepp Health filed its annual report for the year ended December 31, 2025, with the SEC, reflecting the company's ongoing commitment to compliance and transparency, which is crucial for maintaining investor trust.
- Report Access: The annual report will be available on the company's investor relations website and the SEC's site, with shareholders and ADS holders able to request free hard copies, enhancing engagement and communication with investors.
- Market Leadership: Zepp Health stands as a global leader in smart wearables and health technology, leveraging brands like Amazfit, Zepp Clarity, and Zepp Aura to empower users in optimizing their health and fitness journeys, thereby solidifying its market position.
- User Base Expansion: To date, Zepp has shipped over 200 million devices and served more than 53 million users across over 150 countries and regions, demonstrating its extensive global reach and potential for continued growth.
See More
Zepp Health Approaches Breakeven Point
- Financial Performance: Zepp Health reported a loss of $40 million as of December 31, 2025, with a market cap of $235 million, indicating challenges in profitability, yet analysts remain optimistic about its future.
- Breakeven Expectations: Analysts predict that Zepp Health will achieve a profit of $1.5 million in 2026, suggesting that the company is on track to breakeven within the next 12 months, reflecting strong market confidence in its growth potential.
- Growth Rate Requirement: To meet analysts' breakeven forecasts, Zepp Health must achieve an average annual growth rate of 56%, which signals high investor confidence but also highlights potential risks associated with slower growth.
- Debt Levels: Zepp Health's debt constitutes 54% of its equity, exceeding the typical threshold of 40%, which increases investment risk, particularly as the company is not yet profitable.
See More
Zepp Health Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Zepp Health reported Q4 2025 revenue of $85.2 million, a 43% year-over-year increase, with full-year revenue reaching $259 million, reflecting a 41.8% growth from 2024, indicating strong market performance and sustained growth potential.
- Margin Improvement: The gross margin for Q4 2025 reached 40.4%, expanding by 3.6 percentage points from Q4 2024, demonstrating enhanced pricing power and brand recognition, which will contribute to future profitability.
- Strong Product Sales: Amazfit branded product sales surged by 45.4% in Q4 2025, with a full-year growth of 51%, reflecting robust consumer demand for new products and laying a solid foundation for future market expansion.
- Positive Cash Flow Position: The company reported cash and cash equivalents of $113 million in Q4 2025, showcasing a positive operating cash flow that strengthens its liquidity and ability to navigate market fluctuations.
See More
Zepp Health Reports Strong Q4 Revenue Growth
- Earnings Highlights: Zepp Health reported a Q4 non-GAAP EPS loss of -$0.40, yet achieved revenue of $85.17 million, reflecting a robust 43% year-over-year growth, showcasing the company's resilience and growth potential in challenging times.
- Future Guidance: The company anticipates Q1 2026 revenue between $50 million and $55 million, representing a year-over-year increase of 30% to 43%, indicating ongoing improvements in execution and operational efficiency.
- Profitability Improvement: As Zepp Health enters a new phase of growth, the continuous enhancement in profitability underscores its strengthened competitive position, potentially positioning it as a household name in the market.
- Market Reaction: The unexpected turnaround of Zepp Health has garnered market attention, with Seeking Alpha's Quant Rating reflecting optimistic expectations for its future performance, further boosting investor confidence.
See More
Zepp Health Reports Strong 2025 Financial Results
- Significant Revenue Growth: In 2025, Zepp Health achieved total revenues of $258.9 million, a 41.8% year-over-year increase, with Amazfit brand product sales growing by 50.9%, demonstrating the success of its brand transformation and enhancing market competitiveness.
- Record High Gross Margin: The gross margin for Q4 2025 reached 40.4%, up 3.6% from Q4 2024, primarily driven by product mix optimization and enhanced pricing power, with expectations for this trend to continue into 2026.
- Operating Expense Control: Although total operating expenses for Q4 were $38.3 million, an increase from the same period in 2024, the adjusted operating loss significantly decreased to $2.7 million due to effective cost control and revenue growth, indicating progress in financial management.
- Strong Cash Flow: As of December 31, 2025, Zepp Health's cash and cash equivalents stood at $112.9 million, an increase from $110.7 million in 2024, reflecting strong operational performance and tight working capital management, providing ample funding for future investments.
See More
Zepp Health Reports Strong 2025 Financial Results
- Significant Revenue Growth: Zepp Health reported total revenue of $258.9 million for 2025, reflecting a 41.8% year-over-year increase, driven by over 50% sales growth in Amazfit-branded products, indicating strong market performance in the wearable device sector.
- Record Gross Margin: The gross margin for Q4 2025 reached 40.4%, an increase of 3.6 percentage points compared to Q4 2024, showcasing the company's successful optimization of its product mix and ability to maintain pricing integrity during promotional periods, thereby enhancing profitability.
- Substantial Reduction in Net Loss: The net loss for 2025 was $40.1 million, significantly down from $75.7 million in 2024, indicating notable progress in cost control and operational efficiency, with expectations for continued financial improvement.
- Strong Cash Flow: As of December 31, 2025, the company had cash and cash equivalents of $112.9 million, an increase from $110.7 million in 2024, demonstrating robust operational performance and effective working capital management, providing ample resources for future investments.
See More
Zepp Health Files 2025 Annual Report with SEC
- Annual Report Submission: On April 24, 2026, Zepp Health filed its annual report for the year ended December 31, 2025, with the SEC, reflecting the company's ongoing commitment to compliance and transparency, which is crucial for maintaining investor trust.
- Report Access: The annual report will be available on the company's investor relations website and the SEC's site, with shareholders and ADS holders able to request free hard copies, enhancing engagement and communication with investors.
- Market Leadership: Zepp Health stands as a global leader in smart wearables and health technology, leveraging brands like Amazfit, Zepp Clarity, and Zepp Aura to empower users in optimizing their health and fitness journeys, thereby solidifying its market position.
- User Base Expansion: To date, Zepp has shipped over 200 million devices and served more than 53 million users across over 150 countries and regions, demonstrating its extensive global reach and potential for continued growth.
See More
Zepp Health Approaches Breakeven Point
- Financial Performance: Zepp Health reported a loss of $40 million as of December 31, 2025, with a market cap of $235 million, indicating challenges in profitability, yet analysts remain optimistic about its future.
- Breakeven Expectations: Analysts predict that Zepp Health will achieve a profit of $1.5 million in 2026, suggesting that the company is on track to breakeven within the next 12 months, reflecting strong market confidence in its growth potential.
- Growth Rate Requirement: To meet analysts' breakeven forecasts, Zepp Health must achieve an average annual growth rate of 56%, which signals high investor confidence but also highlights potential risks associated with slower growth.
- Debt Levels: Zepp Health's debt constitutes 54% of its equity, exceeding the typical threshold of 40%, which increases investment risk, particularly as the company is not yet profitable.
See More
Zepp Health Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Zepp Health reported Q4 2025 revenue of $85.2 million, a 43% year-over-year increase, with full-year revenue reaching $259 million, reflecting a 41.8% growth from 2024, indicating strong market performance and sustained growth potential.
- Margin Improvement: The gross margin for Q4 2025 reached 40.4%, expanding by 3.6 percentage points from Q4 2024, demonstrating enhanced pricing power and brand recognition, which will contribute to future profitability.
- Strong Product Sales: Amazfit branded product sales surged by 45.4% in Q4 2025, with a full-year growth of 51%, reflecting robust consumer demand for new products and laying a solid foundation for future market expansion.
- Positive Cash Flow Position: The company reported cash and cash equivalents of $113 million in Q4 2025, showcasing a positive operating cash flow that strengthens its liquidity and ability to navigate market fluctuations.
See More
Zepp Health Reports Strong Q4 Revenue Growth
- Earnings Highlights: Zepp Health reported a Q4 non-GAAP EPS loss of -$0.40, yet achieved revenue of $85.17 million, reflecting a robust 43% year-over-year growth, showcasing the company's resilience and growth potential in challenging times.
- Future Guidance: The company anticipates Q1 2026 revenue between $50 million and $55 million, representing a year-over-year increase of 30% to 43%, indicating ongoing improvements in execution and operational efficiency.
- Profitability Improvement: As Zepp Health enters a new phase of growth, the continuous enhancement in profitability underscores its strengthened competitive position, potentially positioning it as a household name in the market.
- Market Reaction: The unexpected turnaround of Zepp Health has garnered market attention, with Seeking Alpha's Quant Rating reflecting optimistic expectations for its future performance, further boosting investor confidence.
See More
Zepp Health Reports Strong 2025 Financial Results
- Significant Revenue Growth: In 2025, Zepp Health achieved total revenues of $258.9 million, a 41.8% year-over-year increase, with Amazfit brand product sales growing by 50.9%, demonstrating the success of its brand transformation and enhancing market competitiveness.
- Record High Gross Margin: The gross margin for Q4 2025 reached 40.4%, up 3.6% from Q4 2024, primarily driven by product mix optimization and enhanced pricing power, with expectations for this trend to continue into 2026.
- Operating Expense Control: Although total operating expenses for Q4 were $38.3 million, an increase from the same period in 2024, the adjusted operating loss significantly decreased to $2.7 million due to effective cost control and revenue growth, indicating progress in financial management.
- Strong Cash Flow: As of December 31, 2025, Zepp Health's cash and cash equivalents stood at $112.9 million, an increase from $110.7 million in 2024, reflecting strong operational performance and tight working capital management, providing ample funding for future investments.
See More
Zepp Health Reports Strong 2025 Financial Results
- Significant Revenue Growth: Zepp Health reported total revenue of $258.9 million for 2025, reflecting a 41.8% year-over-year increase, driven by over 50% sales growth in Amazfit-branded products, indicating strong market performance in the wearable device sector.
- Record Gross Margin: The gross margin for Q4 2025 reached 40.4%, an increase of 3.6 percentage points compared to Q4 2024, showcasing the company's successful optimization of its product mix and ability to maintain pricing integrity during promotional periods, thereby enhancing profitability.
- Substantial Reduction in Net Loss: The net loss for 2025 was $40.1 million, significantly down from $75.7 million in 2024, indicating notable progress in cost control and operational efficiency, with expectations for continued financial improvement.
- Strong Cash Flow: As of December 31, 2025, the company had cash and cash equivalents of $112.9 million, an increase from $110.7 million in 2024, demonstrating robust operational performance and effective working capital management, providing ample resources for future investments.
See More
